[Mefloquine chemoprophylaxis of malaria in the Brazilian Amazonia].

In a randomised double-blind study 122 volunteers living in an endemic malarious area in Amazonian Rondônia state were divided into 4 groups to study malaria suppression. . The first group received 500 mg of mefloquine every month, group II 250 mg every two weeks, group III a tablet of Fansidar (500 mg sulphadoxine + 25mg pyrimethamine) a week and group IV placebo. Acute attacks of malaria occurred in one individual in group I, 2 subject in group II, and 6 individuals in groups III and IV. Protection with mefloquine was significant compared with the placebo group. Both treatment regimens with mefloquine were effective suppressants in an area of high prevalence of drug multiresistant Plasmodium falciparum transmission.

[1]  H. Webster,et al.  Mefloquine-resistant falciparum malaria on the Thai-Burmese border , 1991, The Lancet.

[2]  I. Bygbjerg,et al.  Malaria chemoprophylaxis: why mefloquine? , 1990, The Lancet.

[3]  R. Moyou,et al.  Emergence of mefloquine-resistant malaria in Africa without drug pressure , 1990, The Lancet.

[4]  L. Kerr,et al.  Neuropsychiatric side effects of mefloquine. , 1990, The New England journal of medicine.

[5]  P. Phillips-Howard,et al.  The epidemiology of drug-resistant malaria. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[6]  F. Gay,et al.  Mefloquine failure in child contracting falciparum malaria in West Africa , 1990, The Lancet.

[7]  A. Breckenridge.  Risks and benefits of prophylactic antimalarial drugs. , 1989, BMJ.

[8]  L. Yarzábal,et al.  Susceptibility of Plasmodium falciparum strains to chloroquine and mefloquine in the Amazonas Federal Territory of Venezuela. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[9]  W. Wernsdorfer,et al.  Differences in drug response of Plasmodium falciparum within an area of the Amazon region. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[10]  H. Webster,et al.  Two cases of mefloquine resistant malaria in Thailand. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[11]  W. Kilama,et al.  Low resistance of Plasmodium falciparum to mefloquine in Tanga region, Tanzania. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  A. Prata,et al.  Tratamento de 75 pacientes portadores de malária pelo P. falciparum, em Porto Velho (RO), com mefloquina , 1988 .

[13]  H. Gilles.  The treatment and prophylaxis of malaria. , 1987, Annals of tropical medicine and parasitology.

[14]  W. Wernsdorfer.  Current approaches to malaria chemotherapy and prophylaxis. , 1986, Parasitology Today.

[15]  C. Gilks,et al.  STRATEGIES FOR THE PREVENTION OF MALARIA IN TRAVELLERS: COMPARISON OF DRUG REGIMENS BY MEANS OF RISK-BENEFIT ANALYSIS , 1986, The Lancet.

[16]  W. Peters,et al.  The chemotherapy of rodent malaria, XXVIII. The development of resistance to mefloquine (WR 142,490). , 1977, Annals of tropical medicine and parasitology.

[17]  D. Clyde,et al.  Suppressive Activity of Mefloquine in Sporozoite-Induced Human Malaria , 1976, Antimicrobial Agents and Chemotherapy.

[18]  Clark Dh,et al.  Erythema multiforme and ACTH. , 1953 .

[19]  P. Phillips-Howard,et al.  Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs. , 1990, Bulletin of the World Health Organization.

[20]  J. Chippaux,et al.  Evolution de la chimiosensibilité de Plasmodium falciparum à la chloroquine et à la méfloquine au Bénin entre 1980 et 1989 , 1990 .

[21]  F. Gay,et al.  [Cross resistance to mefloquine and halofantrine in a case of P. falciparum malaria contracted in Sierra Leone]. , 1990, Bulletin de la Société de Pathologie Exotique.

[22]  M. Akogbeto,et al.  [Development of chemoresistance of Plasmodium falciparum to chloroquine and mefloquine in Benin between 1980 and 1989]. , 1990, Bulletin de la Societe de pathologie exotique.

[23]  P. Heizmann,et al.  Single-dose kinetics of mefloquine in Brazilian male subjects. , 1987, Bulletin of the World Health Organization.

[24]  J. M. Souza.  Mefloquine clinical trials - therapeutical experience with mefloquine alone and combination (MSP) in brazilian male subjects with falciparum malaria , 1986 .

[25]  C. H. Osanai,et al.  Resistencia in vivo do "Plasmodium falciparum" as 4-aminoquinoleinas e a associacao sulfadoxina-pirimetamina. II estudo de Manaus, Amazonas 1983-1984 , 1986 .

[26]  B. Greenwood.  The impact of malaria chemoprophylaxis on the immune status of Africans. , 1984, Bulletin of the World Health Organization.

[27]  P. Phintuyothin,et al.  Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine. , 1979, Bulletin of the World Health Organization.